Revenue
2021
2022
2023
2024
LIPELLA PHARMACEUTICALS INC. (LIPO)
Price—Loading quote
Net income
2021
2022
2023
2024
Free cash flow
2023
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
Financial statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue | $536,357 | $449,617 | $184,156 | $259,347 |
| Research & development | $3.6M | $3.0M | $2.5M | $1.5M |
| Operating expenses | $5.6M | $5.2M | $2.8M | $2.2M |
| Operating income | −$5.1M | −$4.7M | −$2.6M | −$1.9M |
| EBITDAderived | −$5.1M | −$4.7M | — | — |
| Net income | −$5.0M | −$4.6M | −$2.6M | −$1.9M |
| Basic EPSper diluted share | -$4.79 | -$6.16 | -$0.64 | -$0.55 |
| Diluted EPSper diluted share | -$4.79 | -$6.16 | -$0.64 | -$0.55 |